Gastric bypass surgery mimetic approaches.

Area of Science:

• Metabolic disease research
• Pharmacological interventions
• Bariatric surgery science

Background:

• Gastric bypass surgery effectively treats obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH).
• Mimetic approaches aim to replicate surgical benefits using pharmacological strategies.
• Individual drug components often show insufficient efficacy for standalone development.

Purpose of the Study:

• To review fixed-dose combinatorial pharmacological approaches that mimic gastric bypass surgery.
• To highlight the essential role of glucagon-like peptide 1 (GLP-1) and fibroblast growth factor 21 (FGF21) in these mimetic strategies.
• To emphasize the preference for fixed-dose combinations over post-approval individual component combinations.

Main Methods:

• Review of existing literature on gastric bypass surgery mimetic approaches.
• Analysis of fixed-dose combinatorial pharmacological strategies.
• Evaluation of the combined efficacy of GLP-1 and FGF21.

Main Results:

• The combination of GLP-1 and FGF21 is crucial for the success of gastric bypass surgery mimetic approaches.
• This dual-action combination shows potential for durable weight loss and improved glycemic control.
• The combination also demonstrates significant reduction in liver lipids, beneficial for NASH treatment.

Conclusions:

• Fixed-dose combinations of GLP-1 and FGF21 represent a viable pharmacological strategy to mimic gastric bypass surgery.
• This approach offers a polypharmacological solution for complex metabolic conditions like obesity, type 2 diabetes, and NASH.
• Fixed-dose combination therapy is preferred due to the limited efficacy of individual components when used alone.